Lumen Bioscience Protocol CDI02 (RePreve)

A randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence.

Read more at:

• https://www.lumen.bio/news/2025/04/02/lmn-201-achieves-100-initial-c-difficile-clinical-cure-in-preliminary-cohort-of-re-preve-trial
• https://www.lumen.bio/news/2025/04/03/investigational-oral-biologic-achieves-100-c-difficile-clinical-cure-in-preliminary-cohort